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Abstract 
Background: Pain is a common and undertreated non-motor symptom in patients with Parkinson’s 
disease (PD). Opioids have been seldom used in PD because they could worsen cognitive and motor 
functions.  
Objective: We aimed to assess efficacy and tolerability of tapentadol in PD patients. 
Methods: We retrospectively reviewed 21 PD patients treated with tapentadol extended release 
(ER) for chronic pain. Patients were evaluated before treatment and at 3 and 6 months during 
treatment for pain intensity (current, 24-hour average, and minimum and worst) with a 0-10 
Numerical Rating Scale and the painDETECT questionnaire; for motor symptom severity with the 
Unified Parkinson’s Disease Rating Scale part III and the Hoehn and Yahr scale; for cognitive 
functions with MiniMental Status Examination, Corsi’s Block Tapping test, Digit Span, Digit-
Symbol Substitution test, FAS test, Rey’s Auditory Verbal Learning test, Trail Making-A and -B, 
and the 9 Hole-Peg Test; for anxiety and depression with the Hospital Anxiety and Depression 
Scale; and for the quality of life with the Short Form-12 for Quality of Life. Data were analyzed by 
one-way ANOVA and paired t-test, and by Friedman’s and Wilcoxon’s test. Statistical significance 
was taken in all cases as P < 0,05. 
Results: Pain intensity decreased over the course of treatment. No differences were found in PD 
symptom severity and dopaminergic drug dosages between pretreatment and treatment evaluations . 
No decrement in cognitive neuropsychological performances was found and an improvement  was 
observed in Digit Span, Digit-Symbol Substitution test and FAS test. The levels of anxiety, 
depression and of quality of life improved. Overall tapentadol ER was well tolerated and most 
patients reported no or mild and short-lived gastroenterological and neurological side effects. 
Conclusions: These results indicate the potential efficacy and tolerability of medium-high dose of 
tapentadol ER for the treatment of pain in PD. 
 
Keywords: Parkinson’s disease, pain, tapentadol, cognitive functions, motor functions. 
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INTRODUCTION 
 
 Pain is one of the most common non-motor symptoms that impairs the quality of life in up to 
80% of Parkinson disease (PD) patients.1-3 Isolated pain symptoms have been associated to a higher 
risk of developing PD and, as other non-motor complaints, can precede for years PD motor 
symptoms.2,3  
 PD patients may present nociceptive musculoskeletal pain because of osteoarthritis of the 
spinal column and large joints or because cramps, dystonia and stiffness caused by PD itself. Further, 
in contrast to the classical view of PD as a dopaminergic syndrome, Braak et colleagues have 
proposed the concept that PD actually initiates at specific Central Nervous System sites and gradually 
evolves in distinct stages.4 In PD preclinical stages I and II, α-synuclein immunoreactive inclusions 
are found first in olfactory nuclei and bulbs and then in brainstem monoaminergic nuclei of locus 
coeruleus and raphe which project to the spinal dorsal horns to modulate pain processing; also, early 
neurodegenerative changes in PD involve nociceptive neurons in the lamina I of the spinal dorsal 
horns.4-6 
Inspite of its incidence, pain in PD is often underdiagnosed and most often treated by 
increasing dopaminergic drugs.7 However, not all types of pain show a clear response to 
dopaminergic therapy. In a recent study, the dopamine agonist rotigonine improved fluctuations 
related pain of King’ PD pain scale but did not affect nocturnal, orofacial and radicular pain; 
rotigonine treatment was actually associated to worsening of the chronic pain domain of King’ PD 
pain scale.8 In PD patients treated with deep brain stimulation, no direct correlation was found 
between sensory/pain changes and motor improvement, suggesting that motor and non-motor 
symptoms of PD do not necessarily share the same mechanisms.9 Further, musculoskeletal pain is 
the most common type of pain in PD occurring most frequently in low back, knee and shoulder.10 
These body sites often present arthritic abnormalities with the advanced age; PD abnormal postures 
can be contributing factors to musculoskeletal pain.10  
Hence, dopaminergic medications are partially effective in controlling PD pain and non-
dopaminergic analgesic agents need to be investigated7. Nonsteroidal anti-inflammatory drugs are 
often considered second-line treatment because of a higher risk of adverse cardiovascular, 
gastrointestinal and renal events, especially in elderly patients.12 On the other hand, physicians are 
reluctant to prescribe opioids to PD patients because they may worsen motor and non-motor 
symptoms such constipation, hallucinations, and daytime sleepiness.7,11 However, in two recent 
(one prospective and one randomized, placebo-controlled) studies, low doses of 
oxycodone/naloxone improved pain intensity in PD patients with no serious adverse effects.13,14 
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However, in the placebo-controlled study, gastroenterological side effects such nausea and 
constipation were found more frequently in the oxycodone- than in the placebo-treated group.14 
 Tapentadol is a relatively new opioid with reduced affinity to the -opioid receptor and a 
serotonin/noradrenaline reuptake inhibitor activity.15 In contrast to morphine and oxycodone, 
tapentadol does not impair hippocampal neurogenesis, and has an improved profile of 
gastrointestinal and Central Nervous System side effects and a negligible risk of abuse.16-19 Also, 
because of its unique noradrenergic features, tapentadol may improve pain in PD by restoring the 
spinal noradrenergic inhibitory tone.15,20,21 
To our knowledge, there are no studies on efficacy and tolerability of tapentandol in PD 
patients. Thus, the aim of this study was to report the effects of tapentadol on pain, motor 
symptoms, cognitive functions and the quality of life in PD patients.  
  
 
 
PATIENTS AND METHODS 
 
Patients 
We retrospectively analyzed PD patients who were treated with tapentadol for pain from 
June 2016 to June 2017, and who met the inclusion and exclusion criteria. The PD patient data were 
part of a longitudinal clinical dataset of the Pain Clinic of Padua University (Italy). Approval of the 
ethics committee was not required for the study because the Italian legislation (law 211/2003) 
attains to clinical research studies and does not provide statements on observational studies on 
routinely collected, anonymous data.  All patients signed an approved consent (DL17-09, Padua 
Hospital Company, Padua, Italy) which allows the anonymous use of their clinical data for research 
purposes.  
Patients were included in the analysis if: 1) they met diagnosis of idiopathic PD according to 
UK Brain Bank criteria; 2) they presented pain lasting > 3 months and with an average 24-hour 
score > 4 measured on a 0–10 Numerical Rating Scale (NRS), despite optimal dopaminergic 
therapy; 3) they presented contraindications and/or lack of efficacy to nonsteroidal anti-
inflammatory drugs and paracetamol; 4) they were on stable L-Dopa dosage in the last month.22 
Patients were not included if: 1) they had already undergone an opioid therapy in the last 6 months; 
2) they presented uncontrolled psychiatric disorders requiring recent hospitalization; 3) they were 
on monoamino oxidase inhibitors therapy.  
 Patients were treated in accordance to drug approved indications and local standard 
guidelines for treating chronic pain. Tapentadol extended release (ER) was titrated with the aim of 
finding for each patient the dose that would provide meaningful pain relief with acceptable side 
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effects. Patients were started on tapentadol ER 25 mg bis in die for 7 days, then 50 mg bis in die for 
7 days. Then, doses could be incremented by 50 mg every week. In case of intolerable side effects, 
tapentadol was down-titrated by 50 mg per week.  
 Pain intensity, vital signs (ie, pulse rate, diastolic and systolic blood pressure, body 
temperature, respiratory rate), body weight, drug dosages and side effects were determined at 
pretreatment baseline, weekly during dose titration, and then monthly when on a stable dose. Motor 
symptom severity, cognitive functions, levels of anxiety and depression, and quality of life were 
determined at pretreatment baseline and at 3 and 6 months of treatment. 
 
Pain  
At each visit, patients were asked to rate their current pain, and their average, minimum and 
worst pain in the last 24 hours, and their average and worst pain in the last month on a 0–10 
Numerical Rating Scale (NRS) (0 = no pain, 10 = extreme pain), and were asked to respond to the 
painDETECT questionnaire, a screening measure for neuropathic pain.23 The painDETECT score 
ranges from -1 to 38 with scores  > 19 suggesting  a high likelihood of neuropathic pain.23 At each 
treatment visit, patients were also asked to rate their pain relief on a 0–100% rating scale. 
 
Parkinson’s disease  
PD motor status and stage were assessed using the Unified Parkinson’s Disease Rating Scale 
(UPDRS) part III and the modified Hoehn and Yahr scale.24,25 
 
Cognitive functions, mood and anxiety, and quality of life assessment 
Cognitive status, mood level and quality of life of PD patients were assessed using a battery 
neuropsychological and psychiatric tests. 
The Mini-Mental Status Examination (MMSE) is a validated instrument to assess global 
cognitive function.26 MMSE ranges from 0 to 30 with lower  scores indicating greater cognitive 
impairment.26  
The Corsi’s Block-Tapping Test (CBT) indices a short-term visuospatial working memory.27 
The patient is required to repeat sequences of increasing length of blocks tapped by the examiner. 
CBT score ranges from 0 to 9 with  higher score corresponding to a better performance.27 
The Digit Span Test (DS) is a component of the Wechsler Intelligence Scale, and assesses 
attention and verbal working memory.28 The patient is asked to repeat series of numbers of 
increasing lengths, in both forward (direct) and backward (reverse) order.28 Scores range from 0 to 
14 in each phase with a higher scores meaning better performance.28 
7 
 
The Digit-Symbol Substitution Test (DSST) is a subscale of the Wechsler Adult Intelligence 
Scale, and is a measure of  mental processing speed, sustained attention and visual spatial abilities.28 
The patient is presented with numbers from 0 to 9 and is instructed to draw under each number the 
corresponding symbol using a key at the top of the page. DSST score ranges from 0 to 93 with a 
higher score indicating a better performance.28 
The F-A-S test (FAS) is a part of the Neurosensory Center Comprehensive Examination for 
Aphasia and assesses verbal fluency. The patient is requested to name as many words as possible 
that begin with the letters F, A, and S, within 1 minute.29 The score is the total number of words; 
higher scores indicate better performances.29 
The Rey’ Auditory Verbal Learning Test (RAVLT) is a neuropsychological test designed to 
evaluate short-term and long-term verbal memory; RAVLT requires encoding, storing and retrieval 
of verbal material.30 RAVLT consists in five learning trials of 15 verbally presented unrelated 
words, followed by an immediate free recall after each trial and by a 20‐min delayed recall after an 
interference list. The RAVLT immediate recall score is the sum of words the patient recalled in the 
first 5 trials; RAVLT delayed recall score is the number of words recalled after a 20 minute 
delayed. Higher scores mean better performances.30 
The Trail-Making Test A and B (TMTA and TMTB) are timed tests of complex visual 
scanning, motor speed, and mental flexibility consisting in 25 circles distributed on a paper sheet. In 
TMTA circles contain numbers (1-25) and in TMTB  numbers (1-13) and letters (A-L). In TMTA, 
the patient is asked to draw a line connecting circles numbered in ascending order, 1 to 25. In 
TMTB, the patient is asked to draw lines connecting circles in ascending order, but alternating 
between numbers and letters, from 1 to A, then A to 2, 2 to B, and at last from 12 to L.31 TMTA and 
TMTB scores are the times taken to complete the tasks with lower time scores indicating better 
performances.31  
The 9 Peg Hole Test (9PHT) is a quantitative timed test of upper extremity function.31 The 
patient is instructed to pick up the nine pegs one at a time as fast as possible and put them in the 
nine holes of a wood block and, once they are all in the holes, to remove them again as fast as 
possible one at a time, and place them back into the container.32 The score is the total time taken to 
place in and remove pegs from the block with lower time scores indicating better performances.  
The Hospital Anxiety and Depression Scale (HADS) is a self-report questionnaire consisting 
of 14 items, seven items measure anxiety and seven depression, weighted on a 4-point (0-3) severity 
Likert scale 33. The maximal score for each subscale is 21 with a higher score indicating worse 
condition and scores > 11 indicating a clinically significant anxiety and/or depression.33  
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The 12-item Short Form Health Survey (SF-12) is an abbreviated version consisting in 12 
items selected from the SF-36. The SF-12 questionnaire was developed to reproduce the two 
physical and mental component summary scores (SF-12 PCS and SF-12 MCS, respectively) and to 
provide an overall health-related quality of life. Higher scores mean better quality of life.34 
 
Tolerability 
 Patients were instructed on the potential side effects of tapentadol ER and, at each visit, they 
were asked whether they had experienced any gastrointestinal side effects such as nausea, vomiting 
and constipation, and/or Central Nervous System side effects such as dizziness, sedation and mental 
confusion, or any new symptom. Constipation was evaluated also with the Bowel Function Index 
(BFI). BFI is based on three variables (ie, ease of defecation, feeling of incomplete bowel 
evacuation, and personal judgement of constipation) which were assessed on a 0-100 NRS and then 
averaged. Then, information on use of prescribed and over-the-counter laxatives and stool softeners 
was requested in order to provide a behavioral measure of constipation. 
 
Statistics 
Data are presented as means ± standard deviations, 95% confidence intervals (95%CI), and 
numbers (and percentages) of patients. Normality was assessed with the Kolmogorov-Smirnov test. 
Normally distributed data were analyzed by one-way repeated-measures analysis of variance 
(ANOVA) and non-normally distributed data were analyzed with Friedman’s test (with a 
Bonferroni correction to adjust for multiple comparisons). When ANOVA was significant; pairwise 
comparisons were perfomed with paired t-test. When Friedman’s test was significant, pairwise 
comparisons were performed using Wilcoxon’s signed rank test (with a Bonferroni correction). 
Categorical variables were assessed with a -square test. All statistical tests were performed in 
SPSS 17.0 (SPSS, USA). Differences were considered statistically significant for values of P < 
0.05.  
 
 
  
RESULTS 
 
Demographics and drug dosages 
Twentyfour PD patients (age 74.0 ± 11.6; 11 males, 10 females; body-mass index 26,2  ± 
3,1; education 8.9 ± 4.8 years; PD duration 5,6 ± 2,3 years) were treated with tapentadol ER 
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between June 2016 and June 2017. Two patients who discontinued treatment in the first weeks 
because of intolerable side effects and one patient who discontinued treatment in the second month 
because of lack of efficacy, were not included in the final analysis. 
Comorbidities were type II diabetes (5 patients, 23%), hypertension (47%), depression 
(23%); active medical therapies were beta-blockers (2 patients, 10%), ACE-inhibitors (24%), Ca++-
antagonists (19%) and antidepressants (19%). 
The vital signs (ie, pulse rate, systolic blood pressure, diastolic blood pressure, respiratory 
rate) and body weight index presented minor, not significant changes during the 6 month treatment 
with tapentadol ER (data not shown).  
All PD patients were on L-Dopa, 8 patients were also on pramipexol and 1 patient on 
ropirinol. The mean L-Dopa dose at baseline was 467,3 ± 245,8 mg/day and remained stable in 17 
of 21 patients during treatment with tapentadol ER; at month 6 of treatment, the mean final dose of 
L-Dopa was 502,5 ± 219,4 mg/day. The dose of tapetandol ER was increased during titration and 
adjusted during maintenance; mean doses of tapentadol ER were 71,3 ± 26,2 and 87,5 ± 25,6 
mg/day at week 2 and month 1 of treatment, and 191,3 ± 69,5 and 206,3 ± 102,7 at month 3 and 6 
of treatment. 
  
  
Effects of tapentadol on pain  
The most frequent pain sites were “limbs” (13 patients, 62%), “low back” (50%), and 
“neck” (15%). Pain was musculoskeletal nociceptive (7 patients, 35%), dystonic (15%), nocturnal 
(25%) and radicular (25%).  
The pain intensity [ie, current, and 24-hour average, least (not shown) and worst)] measured 
on a 0-10 NRS decreased significantly (P < 0,0001 for all measures) during treatment with 
tapentadol ER. The average 24-hour pain was 6,4 ± 1,1 at pretreatment baseline (figure 1) and its 
mean decreases from baseline to month 1, 3, and 6 of treatment were 2,8 ± 1,3 (95%CI, from 2,1 to 
3,4 P = 0,01), 3,1 ± 2,0 (2,2 to 4,1, P < 0,001), and 2,5 ± 2,2 (1,0 to 3,4, P < 0,001). At month 6 of 
treatment, 24-hour pain declined > 50% in 10 patients, between 30 and 50% in 4 patients and < 
30% in 7 patients. Much alike, the current pain NRS decreased from baseline (3,3 ± 2,2) to month 3 
of treatment (mean decrease ± SD 2,2 ± 2,1, 95%CI from 1,2 to 3,2, P < 0,001) and to month 6  of 
treatment (2,1 ± 2,6, 0,5 to 2.9, P = 0,021). A significant reduction was observed also in 24-hour 
worst pain NRS from pretreatment baseline (8,2 ± 1,1) to treatment month 3 and 6 (mean reductions 
± SD 3,6 ± 1,8, 95%CI from 2,7 to 4,4, P = 0,002, and 3,5 ± 2,1, 2,5 to 4,4, P = 0,001).  
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The intensity of neuropathic symptoms decreased (P < 0,0001) during tapentadol treatment 
(table 1). The painDETECT score was 11,4 ± 4,5 at pretreatment baseline and it declined 
significantly from baseline to month 3 (mean decrease ± SD 5,1 ± 4,4, 95%CI from 3,1 to 7,1, P < 
0,0001) and from baseline to month 6 (5,1 ± 4,9, 2,8 to 7,4, P < 0,0001). At the baseline, the 
painDETECT score was < 12 (nociceptive pain) in 11 patients, 13-18 (mixed, nociceptive and 
neuropathic pain) in 7 patients and  > 19 (neuropathic pain) in 3 patients; at the 6 month of 
treatment, painDETECT was < 12 in 18 patients, 13-18 in 3 patients and > 19 (neuropathic) in no 
patient (P = 0,006). 
 
Effects of tapentadol on Parkinson’s disease  
The severity of motor symptoms and the stage of PD were not modified by tapentadol. 
There was no significant difference in scores of UPDRS part III and Hoen-Yahr scale from before 
to during tapentadol treatment (table 1). 
 
Effects of tapentadol on cognitive functions, mood and anxiety, and quality of life  
The scores of MMSE, CBT, DS backward, RAVLT delayed recall and 9HPT were 
unchanged during treatment (table 1). The scores of DS forward, RAVLT immediate recall, HADS 
anxiety and SF-12 PCS improved significantly (P < 0,05) from baseline to treatment month 3 and 
the scores of TMTA, TMTB, DSST,FAS, HADS depression and SF-12 MCS improved from 
baseline to treatment months 3 and 6 (table 1). At the 6 month evaluation on TMTA, 16 of the 21 
patients (76%) performed better, 4 worse (19%) and 1 (5%) the same as baseline; at the 6 month 
evaluation on DSST, fourteen patients (67%) performed better, 2 (10%) worse, and 5 (23%) the 
same as baseline.The intensity of anxiety and depression symptoms decreased significantly (P < 
0,0001 for both measures) during treatment (table 1). HADS scores of anxiety and depression were 
7,3 ± 3,4 and 6,8 ± 3,2 at pretreatment baseline. HADS anxiety score decreased significantly from 
baseline to treatment month 3 (mean decrease ± SD 2,4 ± 2,6, from 1,2 to 3,5, P = 0,003) (table 1) 
and HADS depression score from baseline to treatment months 3 and 6 (mean decreases 2,2 ± 2,4, 
95%CI from 1,1 to 3,3, P = 0,002, and 2,9 ± 3,1, 1,4 to 3,4, P < 0,001) (table 1). In comparison to 
baseline, at treatment month 6 the numbers of patients with significant (HADS >11) anxiety (52 vs 
14%, P = 0,001) and/or depression (43 vs 14%, P = 0,01) decreased significantly.   
Self-rated quality of life improved during treatment with tapentadol ER (table 1); SF-12 PCS 
increased from baseline to month 3 (mean increase ± SD 4,3 ± 4,2, 95% CI from 2,4 to 5,0, P = 
0,002) and the SF-12 MCS from baseline to month 3 and 6 (4,3 ± 4,5, 95%CI from 2,0 to 5,5, P = 
0,001; 3,1 ± 4,5, 95%CI 1,0 to 4,3 P = 0,01).  
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Tolerability 
Tapentadol ERwas well tolerated; adverse events lead to treatment discontinuation in 2 
patients, and were of low-moderate intensity in the remaining 21patients. However, at least one 
transient adverse event was reported by 10 out of 21 patients (47%); 6 patients (29%) reported 
nausea, 3 reported dizziness (14%), 3 sedation/somnolence (14%), and 2 patients (10%) pruritus. 
Tapentadol ER did not worsen PD symptoms (see above). Bowel function as assessed by BFI was 
not altered (P = 0,12) during treatment; mean BFI was 28,2 ± 9,4 at baseline and 29 ± 9,1 and 30 ± 
9,4 at treatment month 3 and 6. 
 
DISCUSSION 
 
 This is, at our knowledge, the first report on efficacy and tolerability of tapentadol ERin PD. 
In this retrospective analysis, tapentadol was effective on pain and well tolerated in PD patients. 
Tapentadol provided a clinically significant and sustained pain relief in most patients. During 
treatment with tapentadol, cognitive and motor functions were unchanged or improved and mood 
level and quality of life improved. The side effect profile of tapentadol and especially the incidence 
of gastrointestinal and Central Nervous System symptoms were similar to those reported in 
previous trials on tapentadol for musculoskeletal pain and on oxycodone/naloxone for pain in PD. 
13,14,17,18 
 Tapentadol ER produced a significant relief in 24-hour average pain already after 1 month of 
treatment (mean decrease from baseline ± SD, 2,8 ± 1,3) and the analgesic relief was sustained. At 
month 3 and 6 of treatment, 24-hour pain declined by > 30% in 67% and 43% of patients. In a 
previous observational study, oxycodone/naloxone 5/2.5 mg bid produced > 30% pain relief after 2 
months of treatment (mean pain NRS decrease 2.31 ± 0.52).13 In a randomized, double-blind, 
placebo-controlled, although it was not superior to placebo at the primary 16 weeks outcome, 
oxycodone/naloxone (mean daily dose 18,8 ± 8,4 mg) reduced pain and yielded to higher rates of 
responders than placebo.14 At week 16 of treatment, responders (> 30% decrease from baseline) 
were 48% in the oxycodone/naloxone group and 34% in the placebo group.14 In our study, we used 
a maintenance daily dose of tapentadol of 206,3 ±102,7 mg that is within the dose-range of 
tapentadol for musculoskeletal pain but is, in terms of opioid equivalent dose, substantially higher 
than doses of oxycodone studied in PD insofar.13,14,17,18,35 These findings suggest that some PD 
patients may tolerate and benefit from doses of opioids higher than previously reported.   
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PD and chronic pain states have both been associated to impaired cognition. The combined 
impact on cognition by PD, chronic pain and chronic opioid therapy has yet to be established and it 
is an important issue because of the reported aggravating effects of opioids on PD.7,10 Consistent 
with previous reports on oxycodone/naloxone, tapentadol ER did not alter measures of global 
cognition.13,14 In this study, tapentadol ER did not impair cognitive functions in PD in 
neuropsychological tests for immediate and delayed verbal memory, spatial memory (ie, CBT, DS, 
RALVT) and hand dexterity (ie, 9PHT). Further, a statistically significant improvement was 
observed in cognitive tests of verbal fluency (ie, FAS), psychomotor speed and pattern recognition 
(ie, DSST) and psychomotor speed and set shifting (ie, TMTA and TMTB). These findings are in 
agreement with studies showing that stable doses of opioids do not have a negative impact on 
cognition and may actually improve cognitive performances in patients with malignant cancer pain 
and non-malignant musculoskeletal pain.36-39 As pain itself can significantly impair cognition in 
healthy subjects and in patients, the cognitive improvement reported here may be due to pain relief. 
40,41 As this study is limited by its retrospective design and by the lack of a control group, a placebo 
effect and/or a practice effect cannot be ruled out. Treatment with tapentadol ER was associated 
with improvement also of both physical and mental component scores of the SF-12. Patients rated 
higher their physical and mental abilities during tapentadol treatment than at baseline. The 
improvement of pain symptoms was associated also to decrease of HADS anxiety and depression 
scores both in patients with clinical depression and in patients with minor depressive symptoms. 
Compared to baseline, after a 6 month therapy with tapentadol were diminished the numbers of 
patients with clinically significant symptoms of  anxiety (52 vs 14%) and depression (43 vs 14%).   
  
The retrospective open-label design, the small number of our patient group, and the lack of a 
control group, represent obvious and important limitations of this study. Although some studies 
found only a low placebo effect in PD, there is ample evidence for a large placebo effect that can be 
estimated in approximately 30% of therapeutic response both in chronic pain patients and in PD 
patients.14,42,43 However, in the present study the magnitude of response to tapentadol was 
significantly higher: 67% and 43% of PD patients reported > 30% pain reduction after 3 and 6 
months of treatment.  
This study had exploratory aims and further studies are warranted to confirm this first 
evidence on the efficacy and tolerability of tapentadol ER in PD. However, these findings support 
the idea that PD patients may benefit in term of analgesia and quality of life from tapentadol in a 
dose range effective in chronic musculoskeletal pain.  
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Table 1. Cognitive and motor functions, anxiety and  mood level, and quality of life in PD  
patients before and during 6 month treatment with tapentadol. 
 
 pretreatment 3 month treatment 6 month treatment  
     
Parkinson disease      
Hoen-Yahr 2,3 ± 0,8 2,4 ± 0,8 2,5 ± 0,8  
UPDRS 28,5 ± 10,5 26,4 ± 10,4 28,4 ± 10,9 
    
Pain symptoms    
24-hour pain NRS 6,4 ± 1,1 3,1 ± 2,0d 2,4 ± 2,2d 
painDETECT 11,4 ± 4,5 6,0 ± 2,6b 6,3 ± 2,5b 
    
Cognitive functions    
MMSE 26,8 ± 1,8 26,7 ± 1,9 26,3 ± 2,2 
CBT 5,0 ± 0,9 5,2 ± 1,1 5,2 ± 1,2 
DS, forward 5,0 ± 1,0 6,3 ± 1,1c 6,3 ± 1,4 
DS, backward 3,0 ± 0,9 3,4 ± 1,1 3,6 ± 1,0 
DSST 24,4  ± 8,8 26,3  ± 8,9d 27,3  ± 9,9d 
FAS test 26,1 ± 10,0 30,5 ± 10,3b 31,5 ± 11,7b 
RALVT immediate recall 24,5 ± 6,7 25,6 ± 6,2b 25,1 ± 6,3 
RALVT delayed recall 3,8 ± 0,9 4,1 ± 1,1 4,0 ± 1,9 
TMTA 60,8 ± 25,5 56,0 ± 24,1b 54,6 ± 26,0b 
TMTB 154,1 ± 111,8 131,5 ± 93,5b 126,9 ± 95,1b 
9PHT 27,8 ± 7,2 26,3 ± 7,2 26,7 ± 6,2 
    
Depression and anxiety    
HADS anxiety 6,6 ± 3,2 5,3 ± 2,8c 5,5 ± 3,2 
HADS depression 6,5 ± 3,3 4,5 ± 2,2d 3,7 ± 2,3d 
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Quality of life    
SF-12 PCS 32,1 ± 8,1 35,8 ± 7.8c 34,3 ± 8,6 
SF-12 MCS 42.3 ± 8,8 46,1 ± 7,7d 45,6 ± 7,9d 
Data are expressed as mean scores ± SD at pretreatment baseline and at treatment month 3 and 6. 
Different from pretreatment: aP < 0,05, bP < 0,01, one-way ANOVA and t-test; : cP < 0,05, dP < 0,01, 
Friedman’s test and Wilcoxon’s signed rank test; .  
Abbreviations: CBT: Corsi’ block tapping test; DS: digit span; HADS, hospital anxiety and 
depression scale; MMSE: MiniMental Status Examination; NRS: numerical rating scale; RALVT, 
Rey’s auditory verbal learning test; SF-12 PCS, SF-12 physical component score; SF-12 MCS, SF-
12 mental component score; TMTA: trail-making test A; TMTB: trail-making test B; UPDRS, 
unified Parkinson’s disease rating scale; 9PHT: 9-peg hole test 
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Figure 1. Mean 24-hour pain NRS in PD patients from pretreatment baseline assessment to 6 month 
treatment assessment; **, P < 0,01, different from baseline. 
